Michael Thomas Massengill, PhD

Michael Massengill practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Michael Massengill's NPI, 1780213025, was assigned on April 8, 2020. Michael Massengill graduated from University Of Florida College Of Medicine in 2020. Michael Massengill holds Florida license ME166869.

Michael Massengill's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Michael Massengill's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Michael Massengill to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Massengill practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Michael Massengill's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Michael Massengill is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Michael Massengill's licenses on file in 2 states: Florida and Illinois.

CMS counts 26 Medicare patients who saw Michael Massengill in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael Massengill's median patient age at 72, with 54% women.

In 2024, Michael Massengill wrote 422 Medicare Part D claims for 121 patients. 64% of them were for generic drugs. CMS names the drug for 357 of them, across 10 drugs with 11 or more claims each, at $14,311 in total drug cost. In 2023, CMS named 498 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Michael Massengill for performance year 2024, reported as part of a group. Michael Massengill accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Michael Massengill, published from 2016 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Disease Models, Animal, Retinitis Pigmentosa and Rhodopsin. Michael Massengill has published most often in Exp Eye Res. Michael Massengill's most frequent co-authors are Jennifer I. Lim, MD, Neil Sheth, MBA, MD and Neil P. Sheth, MD.

CMS Open Payments shows 15 general payments to Michael Massengill from 7 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 65% of the total. Alcon Laboratories Inc paid the most, $1,364.

Michael Massengill graduated from University Of Florida College Of Medicine in 2020.

Michael Massengill is in network with 11 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.